Showing results (11-20 of 443) with videos related to
Sort By:
Pageof 45
Mabs|November 4, 2011
The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scanSeiji Kawa, Masanori Onda, Mitchell Ho, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patientsMitchell Ho, Raffit Hassan, Jingli Zhang, et al.Molecular Cancer Therapeutics|May 7, 2009
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicityYang Feng, Xiaodong Xiao, Zhongyu Zhu, et al.Scientific Reports|May 22, 2015
New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesotheliomaYi-Fan Zhang, Yen Phung, Wei Gao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesotheliomaMasanori Onda, Satoshi Nagata, Mitchell Ho, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Mesothelin expression in human lung cancerMitchell Ho, Tapan K Bera, Mark C Willingham, et al.Cancer Research|May 15, 2014
Discovery of mesothelin and exploiting it as a target for immunotherapyIra Pastan, Raffit HassanCancer Research|January 28, 2010
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptakeYujian Zhang, Johanna K Hansen, Laiman Xiang, et al.Antibody Therapeutics|January 19, 2026
RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapyMasanori Onda, Xiufen Liu, Wenlong Liu, et al.Toxins|January 10, 2019
<i>Pseudomonas</i> Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient's Bedside to Evaluation in Preclinical ModelsYasmin Leshem, Ira PastanPageof 45